

This is a pre print version of the following article:



## AperTO - Archivio Istituzionale Open Access dell'Università di Torino

How to treat patients after natalizumab discontinuation: the TY-STOP 2 study, an Italian, prospective and multicenter study

Original Citation:						
Availability:						
This version is available	http://hdl.handle.net/2318/1757499	since	2020-10-02T10:27:31Z			
Publisher:						
SAGE PUBLICATIONS L	TD					
Terms of use:						
Open Access						
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works						
requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.						

(Article begins on next page)

Abstract: EP1758

Type: ePoster

**Abstract Category:** Therapy - disease modifying - 29 Risk management for disease modifying treatments

Goals: To describe study design, method compare the efficacy an Methods: An Italian, multicenter (8 cent administrations. Patients underwent clini (JCV) antibodies  Results: Recruitment is still ongoing. Up 10.7); median expanded disability status 0.94. 125 patients (90.6%) continued NT of 59/138). During the follow-up, 3 patier of 126 (4.8%) had a clinical relapse in the with available data had an EDSS increas of these have discontinued NTZ. 5/103 p up and 1/9 of these with available information. This descriptive analysis sladue to a better known PML management are and will become available. This will recruitment. Our study will try to identify occurrence  Disclosure: Dr Clerico received person. Merck for editorial collaborations, and has Genzyme.  Dr. Signori received	d patients. After 24 cludy (TY-STOP) ds, state of enrollmed safety tres), prospective, of cal evaluation, mag testing to now 138 patients scale (EDSS) 2.0 (ra Z after 24 courses; of the state of the s	courses, patients and p showed a sto ent, and preliminary resi continuing versus abservational study, en netic resonance imagin every s have been enrolled: r ange: 0-6.5); mean dise. B/13 that discontinued v er 6 months, 4 after 9 a urses. Of these, only 1 l rest 12 months (delta ED ed at least an active MF TZ. 11/74 (14.9%) had a g rate lower (10%) that still a serious NTZ adve a higher number of sw utic strategy preserving of Merck and Biogen for or congresses paid by	hysicians decide whe pping rate of ults of the TY-STOP2 not conting rolling patients after in three mean age at baseline ase duration 8.9 years were JCV-positive (or and 2 after 12. A total and stopped NTZ. 8/8 DSS: median 0 (range RI during the first 12 ran adverse event in the in TY-STOP (65%), erse event and more a vitching patients in or in disease stability and reparticipating to advise Merck, Biogen, Noval	ether to continue about 65%. It study, aimed to buing NTZ. at least 24 NTZ unningham virus months. It study after the study of 6 patients out 7(9.2%) patients out 7(9.2%) and 1 months of follower first 12 months serious). It is probably alternative drugs our, still ongoing, depreventing the PML. Isory boards, by our still, and Sanofi-Novartis.		
Dr. De Mercanti had travel expenses Dr. Artusi had travel expenses for	for congresses congresses paid	paid by Merck, Bioge d by Merck, Biogen	en, Novartis, and S , Novartis, and S	Sanofi-Genzyme. Sanofi-Genzyme.		
Dr. Maniscalco received personal comp Genzyme		speaking or consulta and	ncies from Biogen, f	Novartis, Merck, Teva.		
Dr. Carotenuto	has	nothing	to	disclose.		
Dr. Lanzillo received personal compensations	ion for public speak and	-	m Biogen, Novartis, N	lerck, Genzyme, Almirall.		
Dr. Esposito	has	nothing	to	disclose.		
Dr. Capuano	has	nothing	to	disclose.		
Dr. Bonavita received speaking Dr. Lorefice received speaker fee Dr. Cocco reports personal fees and non- and		serves on scienti		s for Biogen.		
Dr. Annovazzi received honoraria for lec	turing and participat	ion in advisory boards,	and/or travel expens			
congresses and meetings from Merc	ck Serono, Bioger	n, Teva, Sanofi-Aven	tis, Almirall, Roche	and Novartis.		
Dr. Baroncini received honoraria for for expenses for attending congresses a						
Dr. Zaffaroni in the last 2 years receive						
conferences or advisory boards from	om Almirall, Biog	en, Merck, Novartis,	Sanofi-Genzyme,	Roche, Teva.		
Dr. Trebini Dr. Vercellino received consulting	has	nothing	to Riogon Conzum	disclose.		
Dr Cavalla has received Honoraria for						
Novartis.	concentancy or ope	anding morn 7 anninally Di	ogon, oanon,oonzyn	no, moron, rova,		
Dr. Torri Cleri		nothing	to	disclose.		
Dr. Bardina Dr. Rolla	has has	nothing nothing	to to	disclose.		
Dr Durelli received personal compensation by Sanofi-Genzyme for participating to advisory boards, by Merck for editorial						
collaborations, and had travel expense	es for congresses	paid by Merck, Biog	en, Novartis, and S	Sanofi-Genzyme.		
Dr.Sormani received consulting fees from Medday.	n Biogen Idec, Mer	ck Serono, Teva, Genz	zyme, Roche, Novarti	s, GeNeuro and		